Literature DB >> 25289642

Cellular senescence in biliary pathology. Special emphasis on expression of a polycomb group protein EZH2 and a senescent marker p16INK4a in bile ductular tumors and lesions.

Motoko Sasaki1, Yasuni Nakanuma2.   

Abstract

A subgroup of intrahepatic cholangiocarcinoma and combined hepatocellular- cholangiocarcinoma contain a component of cholangiolocellular carcinoma, which is composed of small bile ductular cells. Ductular reaction, a reactive lesion at the portal tract interface comprising increased bile ductules, is frequently seen in chronic advanced liver diseases. Bile duct adenoma, a benign tumor/tumorous lesion is also composed of bile ductular cells. Differential diagnosis among these bile ductular tumors/lesions is sometimes difficult. Given overexpression of a polycomb group protein EZH2 in intrahepatic cholangiocarcinoma and high expression of senescence-associated p16INK4a in ductular reactions, we plan to apply immunostaining for EZH2 and p16INK4a for differential diagnosis of these bile ductular tumors/lesions. The expression of EZH2 was seen in all cases of cholangiolocellular carcinomas, while it was not observed in bile duct adenomas or ductular reactions. In contrast, the expression of p16INK4a was seen in most bile duct adenomas and all ductular reactions, whereas it was barely seen in cholangiolocellular carcinomas. A borderline between cholangiolocellular carcinoma and the surrounding ductular reaction was clearly highlighted by the reverse expression pattern of EZH2 and p16INK4a. In conclusion, immunostaining for EZH2 and p16INK4a may be useful for differential diagnosis for bile ductular tumors/lesions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25289642     DOI: 10.14670/HH-30.267

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  8 in total

1.  Identification of transcription factors (TFs) and targets involved in the cholangiocarcinoma (CCA) by integrated analysis.

Authors:  L Yang; S Feng; Y Yang
Journal:  Cancer Gene Ther       Date:  2016-11-18       Impact factor: 5.987

Review 2.  Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics.

Authors:  Nina Frey; Sascha Venturelli; Lars Zender; Michael Bitzer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-11-29       Impact factor: 46.802

Review 3.  Epithelial cell senescence: an adaptive response to pre-carcinogenic stresses?

Authors:  Corinne Abbadie; Olivier Pluquet; Albin Pourtier
Journal:  Cell Mol Life Sci       Date:  2017-07-13       Impact factor: 9.261

4.  Hedgehog Signaling Overcomes an EZH2-Dependent Epigenetic Barrier to Promote Cholangiocyte Expansion.

Authors:  Nidhi Jalan-Sakrikar; Thiago M De Assuncao; Jie Lu; Luciana L Almada; Gwen Lomberk; Martin E Fernandez-Zapico; Raul Urrutia; Robert C Huebert
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

5.  Receptor-Interacting Protein Kinase 1 Promotes Cholangiocarcinoma Proliferation And Lymphangiogenesis Through The Activation Protein 1 Pathway.

Authors:  Cheng-Zong Li; Yu-Xiang Lin; Tian-Cong Huang; Jun-Yong Pan; Gao-Xiong Wang
Journal:  Onco Targets Ther       Date:  2019-11-01       Impact factor: 4.147

6.  Induction of senescence-associated secretory phenotype underlies the therapeutic efficacy of PRC2 inhibition in cancer.

Authors:  Liping Chu; Yuxiu Qu; Yang An; Linjun Hou; Juewan Li; Weijia Li; Gaofeng Fan; Bao-Liang Song; En Li; Liye Zhang; Wei Qi
Journal:  Cell Death Dis       Date:  2022-02-15       Impact factor: 8.469

7.  Activation of PPARγ/P53 signaling is required for curcumin to induce hepatic stellate cell senescence.

Authors:  H Jin; N Lian; F Zhang; L Chen; Q Chen; C Lu; M Bian; J Shao; L Wu; S Zheng
Journal:  Cell Death Dis       Date:  2016-04-14       Impact factor: 8.469

8.  Interferon-induced protein with tetratricopeptide repeats 3 may be a key factor in primary biliary cholangitis.

Authors:  Motoko Sasaki; Yasunori Sato; Yasuni Nakanuma
Journal:  Sci Rep       Date:  2021-06-01       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.